Milestone Scientific Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Milestone Scientific Inc. develops, patents, and markets computer-controlled drug delivery instruments designed to provide painless, precise injections primarily for medical, dental, and cosmetic applications. Its core products include the CompuFlo® Epidural System for epidural anesthesia with dynamic pressure sensing technology, the STA® Single Tooth Anesthesia system for dental anesthesia, and the CathCheck™ Epidural Catheter Verification System. These products utilize proprietary DPS Dynamic Pressure Sensing Technology® to enhance injection accuracy, patient comfort, and procedural safety. The company targets healthcare providers in medical pain management, dentistry, and cosmetic medicine across a global footprint spanning North America and over 25 countries. Founded in 1998 and headquartered in Roseland, New Jersey, Milestone Scientific operates through direct sales and distribution partnerships, including a strategic alliance with Tri-anim Health Services for U.S. healthcare distribution. Recently, Milestone Scientific appointed Eric Hines as CEO in mid-2025 to drive operational transformation and growth. Under his leadership, the company achieved approximately 20% reduction in operating expenses year-over-year in Q3 2025 alongside modest revenue growth and increased recurring revenue from CompuFlo® disposables. The company secured Medicare Part B payment coverage for the CompuFlo® Epidural System under CPT code 0777T, expanded commercial insurance support, and gained access to U.S. federal healthcare markets via a Federal Supply Schedule contract. Milestone is actively expanding its North American dental sales, bolstering direct and omnichannel marketing efforts for its STA® anesthesia system and relaunching CompuFlo® in medical markets with focused reimbursement strategies. Additionally, it is pursuing new international registrations and partnerships to broaden adoption globally. These efforts are supported by a $14.6 million capital raise closed in 2023 to finance growth initiatives. Milestone Scientific operates within the medical device and dental technology segments, with a product portfolio that includes computerized anesthetic delivery devices, drug delivery instruments for epidural, intra-articular, and local anesthesia, and related disposables. Its technology reduces injection complications associated with traditional syringes and improves procedural outcomes. The company’s key markets include dental practices, pain management clinics, ambulatory surgery centers, and federal government healthcare facilities in the U.S. Milestone's recent operational transformation focuses on cost discipline, expanding commercial reach, scaling infrastructure, and leveraging regulatory and reimbursement advances to accelerate market penetration. Milestone Scientific maintains continuous innovation through its proprietary DPS Dynamic Pressure Sensing Technology® platform, which supports enhanced clinical precision and patient comfort. The company also emphasizes regulatory compliance and market access with ongoing filings and approvals in the U.S. and European Union. It engages actively with healthcare providers and institutions to promote its product adoption and integration into clinical practice. Overall, Milestone Scientific stands as a technology-driven medical research and development company advancing the science of pain management via computer-controlled injection systems, demonstrating steady progress in financial performance, operational efficiencies, and strategic market expansion initiatives under its new leadership team. Its headquarters remain in Roseland, New Jersey, serving a global customer base in over 25 countries through direct and partner-led sales channels.
Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
Milestone Scientific Inc. (MLSS) Q1 2026 Earnings Call Transcript
Milestone Scientific Reports Financial Results for First Quarter 2026
Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
Milestone Scientific Inc. Completes $2.15 Million Private Placement
Milestone Scientific Inc. (MLSS) Q4 2025 Earnings Call Transcript
Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
Milestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call
Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
Milestone Scientific (NYSE:MLSS) Trading Down 2.3% – Here’s What Happened
Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry
Milestone Scientific (NYSE:MLSS) Trading 3.1% Higher – Here’s What Happened
Milestone Scientific (NYSE:MLSS) Shares Down 1.6% – Here’s Why
Milestone Scientific Inc. (MLSS) Q3 2025 Earnings Call Transcript
Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025
Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference Call
Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership
Milestone Scientific Commits to Regaining NYSE American Compliance Following Notification